New Delhi: Market regulator Sebi has received multiple complaints about alleged irregularities in trading of Ranbaxy shares before the announcement of its multi-billion dollar merger deal with Sun Pharmaceutical.
Securities and Exchange Board of India has started collating data related to the matter from stock exchanges and clearing corporations, sources said. In one of the biggest deals in the domestic pharma sector, Sun Pharmaceutical Industries announced on Monday that it would acquire troubled rival Ranbaxy Laboratories in a USD 4-billion deal that includes USD 800 million debt.
Shares of Ranbaxy had witnessed substantial movements on the exchanges last week itself. From March 31 to April 4, shares of Ranbaxy jumped 26 per cent. The scrip today closed at Rs 467 on the BSE. The sources said Sebi has received multiple complaints regarding suspected irregularities in the trading of Ranbaxy shares in the run up to the deal announcement. During that period, there have been heavy intra-day surges in volumes as well as prices of Ranbaxy shares.
Complaints have been received from various quarters including brokers, investor associations, proxy advisory firms, fund houses, Foreign Institutional Investors and Association of National Exchanges Members of India, the sources said. The capital market watchdog has started collating data related to movement in Ranbaxy shares including from stock exchanges and clearing corporations, sources said. Sebi is also gleaning data available on its Integrated Market Surveillance System. Through IMSS, it collects data for suspicious market activities through multiple sources, including its network systems at stock exchanges and other market infrastructure institutions.
According to sources, exchanges were believed to have been informed about the Ranbaxy deal after the midnight on Sunday. Entities suspected of having prior information about the deal before the official announcement are under the scanner, they added. The combination of Sun Pharma and Ranbaxy would create the country's largest pharmaceutical company with an estimated combined revenue of USD 4.2 billion. The entity would also be the fifth-largest speciality generics company in the world.
Meanwhile, Sun Pharma today denied insider allegations of trading against Silverstreet Developers LLP, a wholly owned arm, related to the deal with Ranbaxy. In a statement, Sun Pharma said the matter related to purchase of shares of Ranbaxy by Silverstreet Developers LLP "does not violate insider trading rules”.
